H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the 11 Best Stocks to Buy for Investment.

On January 9, H.C. Wainwright reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO), maintaining the price target at $90. Mitchell Kapoor from H.C. Wainwright remains positive on HALO, considering the strategic and financial strength of its ENHANZE platform. Kapoor believes the recent business developments with Takeda and Skye are a significant win for the company, expanding ENHANZE’s reach beyond oncology. The analyst expects these deals to help ENHANZE reach into large and durable markets such as inflammatory bowel disease and obesity.

In other news, on January 8, Morgan Stanley slightly lowered the price target on HALO from $79 to 75, keeping an Overweight rating. The analyst at Morgan Stanley expects small-to-mid-cap U.S. biotech stocks to outperform in 2026 as commercial names shift from ‘capital consumers to producers.’ The analyst sees large-cap biopharma companies facing a looming patent cliff.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on the research, development, and commercialization of proprietary enzymes and devices worldwide.

While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best New Penny Stocks to Invest In and 13 Best Gold Mining Companies to Invest In Now.

Disclosure: None. This article is originally published at Insider Monkey.